Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase 2/3 trial to evaluate safety and efficacy of DEP® SN38 in patients with platinum-resistant ovarian cancer

Next Previous
Trial Profile

A phase 2/3 trial to evaluate safety and efficacy of DEP® SN38 in patients with platinum-resistant ovarian cancer

Status: Planning
Phase of Trial: Phase II/III

Latest Information Update: 24 Feb 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Irinotecan (Primary) ; Doxorubicin liposomal; Paclitaxel; Topotecan
  • Indications Ovarian cancer
  • Focus Adverse reactions; Therapeutic Use

Most Recent Events

  • 24 Feb 2025 According to a Starpharma media release, the company announced that ,the FDA agreed with Starpharmas proposal that DEP SN38 could be considered for FDA Fast Track designation, also the FDA indicated that DEP SN38 may qualify for accelerated approval based on an interim analysis of early surrogate endpoints from this proposed Phase 2/3 clinical trial program.
  • 24 Feb 2025 According to a Starpharma media release, the company to day announced that a positive development regarding its DEP SN38 (DEP irinotecan) program following a meeting with the US Food and Drug Administration (FDA), the purpose of the meeting was to confirm the regulatory approval pathways and seek regulatory guidance on the design of a Phase 2/3 clinical program aimed at obtaining registration for DEP SN38 in patients with platinum-resistant ovarian cancer in the US.
  • 24 Feb 2025 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top